読み込み中
Boundless Bio, Inc., a clinical-stage oncology company, focuses on developing innovative cancer therapies aimed at addressing the significant unmet needs of patients with oncogene amplified tumors. Their core strategy involves targeting extrachromosomal DNA (ecDNA). The company's lead product candidate, BBI-355, an orally administered inhibitor of checkpoint kinase 1 (CHK1), is currently in Phase 1/2 clinical trials for patients suffering from oncogene amplified cancers. Additionally, Boundless Bio is advancing BBI-825, another oral inhibitor, this one targeting ribonucleotide reductase (RNR), also in Phase 1/2 clinical development for cancer patients exhibiting resistance gene amplifications. A third initiative, the ecDTx 3 program, is designed to target a kinesin crucial for the cellular segregation mechanism of ecDNA. Incorporated in 2018, the company originally operated as Pretzel Therapeutics, Inc. before adopting the name Boundless Bio, Inc. in July 2019. Its headquarters are situated in San Diego, California.
前日終値
$2.53
−$0.05 · -1.94%
日中の時刻はETです。市場データは遅延する場合があります。
Boundless Bio, Inc., a clinical-stage oncology company, focuses on developing innovative cancer therapies aimed at addressing the significant unmet needs of patients with oncogene amplified tumors. Their core strategy involves targeting extrachromosomal DNA (ecDNA). The company's lead product candidate, BBI-355, an orally administered inhibitor of checkpoint kinase 1 (CHK1), is currently in Phase 1/2 clinical trials for patients suffering from oncogene amplified cancers. Additionally, Boundless Bio is advancing BBI-825, another oral inhibitor, this one targeting ribonucleotide reductase (RNR), also in Phase 1/2 clinical development for cancer patients exhibiting resistance gene amplifications. A third initiative, the ecDTx 3 program, is designed to target a kinesin crucial for the cellular segregation mechanism of ecDNA. Incorporated in 2018, the company originally operated as Pretzel Therapeutics, Inc. before adopting the name Boundless Bio, Inc. in July 2019. Its headquarters are situated in San Diego, California.
日中レンジ
現在 $2.53
52週レンジ
現在 $2.53
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
33
割高
センチメント
53
まちまち
リスク
45
やや高いリスク
モメンタム
63
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Boundless Bio, Inc., a clinical-stage oncology company, focuses on developing innovative cancer therapies aimed at addressing the significant unmet needs of patients with oncogene amplified tumors. Their core strategy involves targeting extrachromosomal DNA (ecDNA). The company's lead product candidate, BBI-355, an orally administered inhibitor of checkpoint kinase 1 (CHK1), is currently in Phase 1/2 clinical trials for patients suffering from oncogene amplified cancers. Additionally, Boundless Bio is advancing BBI-825, another oral inhibitor, this one targeting ribonucleotide reductase (RNR), also in Phase 1/2 clinical development for cancer patients exhibiting resistance gene amplifications. A third initiative, the ecDTx 3 program, is designed to target a kinesin crucial for the cellular segregation mechanism of ecDNA. Incorporated in 2018, the company originally operated as Pretzel Therapeutics, Inc. before adopting the name Boundless Bio, Inc. in July 2019. Its headquarters are situated in San Diego, California.
日中レンジ
現在 $2.53
52週レンジ
現在 $2.53
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上原価 | 125.1万 USD | 108.6万 USD | — | — | — |
| 粗利益 | −125.1万 USD | −108.6万 USD | — | — | — |
| 研究開発 | 4484.5万 USD | 5526.7万 USD | 4263.7万 USD | 3715.9万 USD | 1927.8万 USD |
| 販売・一般管理 | 1870.7万 USD | 1800万 USD | 1215.9万 USD | 931万 USD | 602.3万 USD |
| 営業費用 | 6230.1万 USD | 7218.1万 USD | 5479.6万 USD | 4646.9万 USD | 2530.1万 USD |
| 受取利息 | 535.7万 USD | 789.2万 USD | 528.2万 USD | 66.8万 USD | 9.6万 USD |
| 減価償却費と償却費 | 125.1万 USD | 108.6万 USD | 95.7万 USD | 94.2万 USD | 68.2万 USD |
| 営業利益 | −6355.2万 USD | −7326.7万 USD | −5479.6万 USD | −4646.9万 USD | −2530.1万 USD |
| 純利益 | −5819.7万 USD | −6536.3万 USD | −4943.4万 USD | −4590.1万 USD | −2521万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
この株式へのエクスポージャーを報告している上場投資信託です。
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
